Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.70 |
| ▸ | REN | P00797 | 4/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | F2 | P00734 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | LTA4H | P09960 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | PEPD | P12955 | 1/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.70 |
| ▸ | HTR2A | P28223 | 1/20 | 0.70 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.70 |
| ▸ | HRH1 | P35367 | 1/20 | 0.70 |
| ▸ | THPO | P40225 | 1/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2443468 | 1.00 | ACE (0.70) | ACERENKDM4EF2LMNA | |
| SCHEMBL11212417 | 1.00 | ACE (0.70) | ACERENKDM4EF2LMNA | |
| SCHEMBL6783588 | 1.00 | ACE (0.70) | ACERENKDM4EF2LMNA | |
| SCHEMBL8094713 | 1.00 | ACE (0.70) | ACERENKDM4EF2LMNA | |
| SCHEMBL683117 | 1.00 | ACE (0.70) | ACERENKDM4EF2LMNA | |
| SCHEMBL18158948 | 0.96 | ACE (0.65) | ACERENKDM4EF2LMNA | |
| SCHEMBL18158950 | 0.96 | ACE (0.65) | ACERENKDM4EF2LMNA | |
| SCHEMBL10935359 | 0.92 | ACE (0.60) | ACERENKDM4EF2LMNA | |
| SCHEMBL4385014 | 0.91 | ACE (0.67) | ACERENKDM4EF2LMNA | |
| SCHEMBL4385017 | 0.91 | ACE (0.67) | ACERENKDM4EF2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110146624-B | Detection method of captopril related substances | 湖南汉森制药股份有限公司 | 2022-02-22 | — | — | CN | claimed |
| CN-110850004-A | Checking method of captopril tablets | 仁和堂药业有限公司 | 2020-02-28 | — | — | CN | claimed |
| CN-110612119-A | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | 西雅图儿童医院（DBA西雅图儿童研究所） | 2019-12-24 | — | — | CN | claimed |
| WO-2018148224-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2018-08-16 | — | — | WO | claimed |
| CN-104991028-B | The reduction method of fixedness buffer salt content in LC MS testers | 北京市药品检验所 | 2017-10-31 | — | — | CN | claimed |
| CN-104991027-B | The method for reducing fixedness buffer salt content in LC MS testers | 北京市药品检验所 | 2017-10-17 | — | — | CN | claimed |
| CN-105092733-B | The reduction method and apparatus of fixedness buffer salt content in LC MS testers | 北京市药品检验所 | 2017-09-26 | — | — | CN | claimed |
| CN-105092745-B | The method and apparatus for reducing fixedness buffer salt content in LC MS testers | 北京市药品检验所 | 2017-09-12 | — | — | CN | claimed |
| CN-102768243-A | Inspection method of compound compound captopril tablets | JIANGUANG GU | 2012-11-07 | — | — | CN | claimed |
| US-20030176512-A1 | Asymmetric disulfides and methods of using same | PROLX PHARMACEUTICALS CORPORATION (CA) | 2003-09-18 | — | — | US | claimed |
| JP-8040896-A | — | — | None | — | — | JP | disclosed |
| US-20250215107-A1 | MULTISPECIFIC NK ENGAGER PROTEIN | INNATE PHARMA (FR) | 2025-07-03 | — | — | US | disclosed |
| US-12252543-B2 | Multispecific NK engager protein | INNATE PHARMA (FR) | 2025-03-18 | — | — | US | disclosed |
| EP-3313876-B1 | MULTISPECIFIC ANTIGEN BINDING PROTEINS | INNATE PHARMA (FR) | 2025-01-22 | — | — | EP | disclosed |
| CN-110612119-B | Phosphatidylether (PLE) CAR T cell tumor targeting (CTCT) agents | 西雅图儿童医院（DBA西雅图儿童研究所） | 2024-10-29 | — | — | CN | disclosed |
| EP-0879050-A1 | CAPTOPRIL TABLETS | EGIS GYOGYSZERGYAR RT. (HU) | 1998-11-25 | — | — | EP | disclosed |
| WO-1998010753-A1 | CAPTOPRIL TABLETS | EGIS Gyógyszergyár Rt. (HU) | 1998-03-19 | — | — | WO | disclosed |
| EP-0802182-A1 | PROCESS FOR PRODUCING N-(D-$g(a)-METHYL-$g(b)-MERCAPTOPROPIONYL)-L-PROLINE AND INTERMEDIATES THEREOF | KANEKA CORPORATION (JP) | 1997-10-22 | — | — | EP | disclosed |
| JP-H0840896-A | MEDICAL PREPARATION COMPOSED OF CAPTOPRIL ANALOGUE | TEISAN SEIYAKU KK | 1996-02-13 | — | — | JP | disclosed |
| US-5433951-A | Sustained release formulation containing captopril and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215107-A1 | MULTISPECIFIC NK ENGAGER PROTEIN | KLRK1, FCGR3B, LENG8 | ACE 3359/4885REN 3878/4885KDM4E 746/4885 |
| US-12252543-B2 | Multispecific NK engager protein | KLRK1, FCGR3B, LENG8 | ACE 3359/4885REN 3878/4885KDM4E 746/4885 |
| US-20030176512-A1 | Asymmetric disulfides and methods of using same | PRDX3, PDIA5, PRDX5 | ACE 4407/4885REN 3184/4885KDM4E 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.